INHIBITION OF ANGIOGENESIS BY BLEOMYCIN AND ITS COPPER COMPLEX

Tsutomu OIKAWA; Kenji HIROTANI; Hiroyuki OGASAWARA; Takashi KATAYAMA; Hiromi ASHINOFUSE; Mariko SHIMAMURA; Takao IWAGUCHI; Osamu NAKAMURA

doi:10.1248/cpb.38.1790

Tsutomu OIKAWA, Kenji HIROTANI, Hiroyuki OGASAWARA, Takashi KATAYAMA, Hiromi ASHINOFUSE, Mariko SHIMAMURA, Takao IWAGUCHI, Osamu NAKAMURA

Author information

Tsutomu OIKAWA
Kenji HIROTANI
Hiroyuki OGASAWARA
Takashi KATAYAMA
Hiromi ASHINOFUSE
Mariko SHIMAMURA
Takao IWAGUCHI
Osamu NAKAMURA
Author's Organization：
Division of Cancer Therapeutics, The Tokyo Metropolitan Institute of Medical Science
Division of Cancer Therapeutics, The Tokyo Metropolitan Institute of Medical Science:Faculty of Pharmaceutical Sciences, Science University of Tokyo
Division of Cancer Therapeutics, The Tokyo Metropolitan Institute of Medical Science:Faculty of Pharmaceutical Sciences, Science University of Tokyo
Faculty of Pharmaceutical Sciences, Science University of Tokyo
Division of Cancer Therapeutics, The Tokyo Metropolitan Institute of Medical Science
Division of Cancer Therapeutics, The Tokyo Metropolitan Institute of Medical Science
Division of Cancer Therapeutics, The Tokyo Metropolitan Institute of Medical Science
Division of Neurosurgery, The Tokyo Metropolitan Komagome Hospital

Keywords: bleomycin, copper-bleomycin complex, embryonic angiogenesis, chorioallantoic membrane, angiogenesis inhibition

JOURNAL FREE ACCESS

1990 Volume 38 Issue 6 Pages 1790-1792

DOI https://doi.org/10.1248/cpb.38.1790

Details

Abstract

The effects of bleomycin (BLM) and its copper complex on embryonic angiogenesis were studied in the chorioallantoic membranes of 4.5-day-old chick embryos. Copper-free BLM inhibited embryonic angiogenesis in a dose-dependent manner, with activity detectable at 1 ng/egg and maximal at 1000 ng/egg. Also, treatment with copper-BLM complex dose-dependently caused inhibition of embryonic angiogenesis in a lower dose range. Since tumor growth is believed to depend on angiogenesis, the present results may indicate that the antiangiogenic activity of BLM is, at least in part, implicated in the antitumor activity of the drug.

Corresponding author

Register with J-STAGE for free!